Literature DB >> 27303081

Patiromer.

Dennis J Cada, Jessica Dang, Danial E Baker.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The April 2016 monograph topics are von Willebrand factor (recombinant), daratumumab, elotuzumab, uridine triacetate, and ixazomib. The MUE is on lesinurad.

Entities:  

Year:  2016        PMID: 27303081      PMCID: PMC4896336          DOI: 10.1310/hpj5104-328

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  10 in total

Review 1.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

Review 2.  Pathogenesis, diagnosis and management of hyperkalemia.

Authors:  Anja Lehnhardt; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

3.  Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Authors:  George L Bakris; Bertram Pitt; Matthew R Weir; Mason W Freeman; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Rezi Zawadzki; Lance Berman; David A Bushinsky
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

4.  A new era for the treatment of hyperkalemia?

Authors:  Julie R Ingelfinger
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

5.  Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Authors:  Matthew R Weir; George L Bakris; David A Bushinsky; Martha R Mayo; Dahlia Garza; Yuri Stasiv; Janet Wittes; Heidi Christ-Schmidt; Lance Berman; Bertram Pitt
Journal:  N Engl J Med       Date:  2014-11-21       Impact factor: 91.245

Review 6.  Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate.

Authors:  Timothy Nguyen; Daniella Ondrik; Oksana Zhufyak; Watson To; Sining He
Journal:  JAAPA       Date:  2015-03

Review 7.  Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.

Authors:  Raquel Esteras; Maria Vanessa Perez-Gomez; Laura Rodriguez-Osorio; Alberto Ortiz; Beatriz Fernandez-Fernandez
Journal:  Ther Adv Drug Saf       Date:  2015-08

8.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.

Authors:  Bertram Pitt; Stefan D Anker; David A Bushinsky; Dalane W Kitzman; Faiez Zannad; I-Zu Huang
Journal:  Eur Heart J       Date:  2011-01-05       Impact factor: 29.983

9.  Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.

Authors:  David A Bushinsky; Gordon H Williams; Bertram Pitt; Matthew R Weir; Mason W Freeman; Dahlia Garza; Yuri Stasiv; Elizabeth Li; Lance Berman; George L Bakris
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

10.  Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.

Authors:  Bertram Pitt; George L Bakris; David A Bushinsky; Dahlia Garza; Martha R Mayo; Yuri Stasiv; Heidi Christ-Schmidt; Lance Berman; Matthew R Weir
Journal:  Eur J Heart Fail       Date:  2015-10-12       Impact factor: 15.534

  10 in total
  1 in total

1.  Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review.

Authors:  Fabiana R Varallo; Victória Trombotto; Rosa C Lucchetta; Patricia de C Mastroianni
Journal:  Pharm Pract (Granada)       Date:  2019-03-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.